Advertisement

Topics

In psoriatic arthritis, TNFi drug-level testing may predict 12-month response

11:00 EDT 21 Jun 2017 | Healio

MADRID — In psoriatic arthritis patients initiating an adalimumab regimen, tumor necrosis factor-alpha inhibitor drug-level testing may have utility in determining 12-month treatment response and disability, according to findings presented at the EULAR Annual Congress. Moreover, an inverse relationship to drug levels was observed for both the presence of antidrug antibodies and BMI, the study found.

Original Article: In psoriatic arthritis, TNFi drug-level testing may predict 12-month response

NEXT ARTICLE

More From BioPortfolio on "In psoriatic arthritis, TNFi drug-level testing may predict 12-month response"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...